Nerve Block for Sarcoma Pain Management After Surgery

Recruiting in Palo Alto (17 mi)

Overseen byChristopher P. Scally

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decrease dependency on opioid medications for pain relief after surgery and prevent long-term use and addiction.

Research Team

Christopher P. Scally

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for patients having elective open surgery to remove retroperitoneal sarcoma, who would normally receive pain management with a QL block and IV-PCA. It's not for those expected to be discharged within 4 days post-surgery or with a history of substance abuse.

Inclusion Criteria

I am having surgery to remove a sarcoma and will be given specific pain management.

Exclusion Criteria

I am having or had a surgery with small cuts.

Cases in which anticipated discharge is on or before postoperative day 4

You have struggled with drug or alcohol addiction in the past or currently.

Treatment Details

Interventions

Liposomal Bupivacaine (Local Anesthetic)
Quadratus Lumborum Block (Local Anesthetic)

Trial OverviewThe study is testing if giving a repeat injection of liposomal bupivacaine (a numbing medication) as part of the QL block can reduce opioid prescriptions after surgery, potentially decreasing long-term use and addiction risks.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm II (liposomal bupivacaine)Experimental Treatment3 Interventions

Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.

Group II: Arm I (liposomal bupivacaine)Active Control3 Interventions